US court invalidates Lilly's Gemzar method-of-use patent
This article was originally published in Scrip
Executive Summary
A US appeals court has upheld a previous ruling invalidating Lilly's method-of-use patent for its anticancer, Gemzar (gemcitabine HCl for injection).